$GRAL (GRAIL Inc.) — investor discussion on X

Five-factor rating: Sell (sector percentile 20.7%)

Graded daily on value D, growth C+, profitability F, momentum A, revisions B. Sector-relative, identical for every user.

Most active credible voices on $GRAL

@stevedjacobs (Steve Jacobs) — 12 mentions · 17.0K followers
@hedgefundtips (Thomas J. Hayes) — 10 mentions · 72.4K followers
@fundmyfund (Fund.TBD $UMAC $LPTH 🐋) — 10 mentions · 13.7K followers

Recent headlines featuring $GRAL

2026-09-24: FDA panel backs Grail’s multi-cancer blood test

Pro Analysis Available: Full unrolled post citations, institutional 13F filing matrix, and real-time sentiment alerts for $GRAL are available with SpikePanel Pro.

Stock Ratings · Today Headlines · SpikePanel

For richer charts and full features, open SpikePanel on desktop.

$GRAL — what investors on X are saying · SpikePanel

$GRALGRAIL Inc. · Medical - Diagnostics & Research · $5.6B

$125.64

post0.0%

Event thread

Key events, in time order

10 items

2026-11-05Earnings
GRAIL Q3 Revenue Up 4% on Volume, Price Cuts Ahead of FDA
Q3 revenue +4% as volume gains offset by lower prices; early 2027 FDA decision expected
D1 -17.1% · since +4.7%
2026-11-04Earnings
Earnings report
D1 +3.0% · since -13.2%

8 earlier events

2026-10-01Capital
GRAL Hits New 52-Week High on Heavy Volume
Price reached $151.46 with volume over 1.92M shares, indicating heightened market interest
D1 -5.4% · +5d +0.0%
2026-09-23Trading halt
Halt: news pending
D1 +0.0% · +5d +29.1%
2026-08-11Earnings
Earnings report
D1 +0.9% · +5d -6.1%
2026-08-058-K filing
8-K: Item 2.02, Item 9.01
D1 +2.0% · +5d -7.1%
2026-08-05Earnings
Earnings report
D1 +2.0% · +5d -7.1%
2026-07-13 → 08-04RegulationBear
GRAIL Faces Multiple Securities Class Actions Alleging Fraud
Multiple firms issued reminders today; August 4 is the first deadline for lead plaintiff applications.
D1 -0.3% · +5d -4.0%
23 waves of this story
- 2026-07-13 At least 4 independent firms filed suits for buyers from May 13 to Feb 19, alleging misleading trial results
- 2026-07-14 Multiple firms remind investors of Aug 4 deadline, alleging NHS-Galleri trial misrepresentations
- 2026-07-15 Multiple law firms announce class actions alleging GRAIL misled investors on NHS-Galleri trial, stock fell 50%.
- 2026-07-16 Multiple firms alert investors; suits allege misrepresentations on NHS-Galleri trial; deadline approaches
- 2026-07-17 Multiple firms remind of Aug 4 deadline; allegations focus on concealing adverse NHS-Galleri data trends
- 2026-07-17 At least 7 law firms issued alerts; class period and deadline confirmed, event intensifying
- 2026-07-19 Two additional firms (Rosen, Faruqi & Faruqi) issued reminders, specifying class period May 13, 2025-Feb 19, 2026, with deadline Aug 4, 2026.
- 2026-07-20 Multiple law firms remind investors of Aug 4 deadline; claims linked to NHS-Galleri trial failure.
- 2026-07-22 Multiple law firms issue reminders, investors must act before August 4 deadline; class period covers May 13, 2025 to Feb 19, 2026.
- 2026-07-22 Multiple firms remind investors of Aug 4 deadline; suit relates to failed NHS-Galleri trial
- 2026-07-24 At least 7 law firms issued alerts on July 23-24, urging investors to join the lawsuit before the August 4 deadline, alleging misrepresentations about trial results
- 2026-07-25 At least 6 independent law firms issued notices; class period set May 13, 2025 to Feb 19, 2026
- 2026-07-25 Multiple firms confirm August 4 lead plaintiff deadline; alleged class period May 13, 2025 to Feb 19, 2026
- 2026-07-27 Multiple firms remind of Aug 4 lead plaintiff deadline; class period May 13, 2025 to Feb 19, 2026
- 2026-07-28 Multiple firms remind of Aug 4 deadline after 50% stock drop.
- 2026-07-29 Multiple law firms announce class actions alleging GRAIL misled investors on NHS-Galleri trial; stock fell 50%; lead plaintiff deadline Aug 4.
- 2026-07-29 Multiple law firms re-issue reminders, investors must contact by Aug 4, class period May 13, 2025 - Feb 19, 2026
- 2026-07-31 Multiple law firms issue reminders, class action alleges securities fraud, investors must act by Aug 4
- 2026-08-01 Multiple law firms (BFA, Bronstein, DJS, Faruqi, Rosen, SBS, Gross, Robbins Geller) issued reminders today, with August 4 as the first deadline; class period alleged May 13, 2025 to Feb 19, 2026.
- 2026-08-01 Multiple law firms remind investors of August 4 deadline; class period covers May 13, 2025 to Feb 19, 2026
- 2026-08-03 Multiple firms remind of Aug 4 deadline for lead plaintiff applications
- 2026-08-04 Lead plaintiff deadline Aug 4; multiple firms issue reminders; alleged class period May 13, 2025–Feb 19, 2026
- 2026-08-04 Multiple firms issued reminders today; August 4 is the first deadline for lead plaintiff applications.
2026-07-30Company
GRAIL to Present at Canaccord Genuity 46th Annual Growth Conference
Management to attend, may discuss business progress and strategy
D1 +12.1% · +5d -10.9%
2026-07-29Earnings
GRAIL to Announce Second Quarter 2026 Financial Results
Company plans to release Q2 2026 financial results soon, exact date to be announced
D1 -1.5% · +5d +16.9%

①

Bull vs bear

by direction · sourced

Bull signals0

None yet

Bear signals0

None yet

Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice

⑩

Discussion

be the first

Be civil · your views are your own

No comments yet.

Facts and opinions separated · All items sourced · Not investment advice

Event thread

Key events, in time order

10 items

2026-11-05Earnings
GRAIL Q3 Revenue Up 4% on Volume, Price Cuts Ahead of FDA
Q3 revenue +4% as volume gains offset by lower prices; early 2027 FDA decision expected
D1 -17.1% · since +4.7%
2026-11-04Earnings
Earnings report
D1 +3.0% · since -13.2%
2026-10-01Capital
GRAL Hits New 52-Week High on Heavy Volume
Price reached $151.46 with volume over 1.92M shares, indicating heightened market interest
D1 -5.4% · +5d +0.0%
2026-09-23Trading halt
Halt: news pending
D1 +0.0% · +5d +29.1%
2026-08-11Earnings
Earnings report
D1 +0.9% · +5d -6.1%

5 earlier events

2026-08-058-K filing
8-K: Item 2.02, Item 9.01
D1 +2.0% · +5d -7.1%
2026-08-05Earnings
Earnings report
D1 +2.0% · +5d -7.1%
2026-07-13 → 08-04RegulationBear
GRAIL Faces Multiple Securities Class Actions Alleging Fraud
Multiple firms issued reminders today; August 4 is the first deadline for lead plaintiff applications.
D1 -0.3% · +5d -4.0%
23 waves of this story
- 2026-07-13 At least 4 independent firms filed suits for buyers from May 13 to Feb 19, alleging misleading trial results
- 2026-07-14 Multiple firms remind investors of Aug 4 deadline, alleging NHS-Galleri trial misrepresentations
- 2026-07-15 Multiple law firms announce class actions alleging GRAIL misled investors on NHS-Galleri trial, stock fell 50%.
- 2026-07-16 Multiple firms alert investors; suits allege misrepresentations on NHS-Galleri trial; deadline approaches
- 2026-07-17 Multiple firms remind of Aug 4 deadline; allegations focus on concealing adverse NHS-Galleri data trends
- 2026-07-17 At least 7 law firms issued alerts; class period and deadline confirmed, event intensifying
- 2026-07-19 Two additional firms (Rosen, Faruqi & Faruqi) issued reminders, specifying class period May 13, 2025-Feb 19, 2026, with deadline Aug 4, 2026.
- 2026-07-20 Multiple law firms remind investors of Aug 4 deadline; claims linked to NHS-Galleri trial failure.
- 2026-07-22 Multiple law firms issue reminders, investors must act before August 4 deadline; class period covers May 13, 2025 to Feb 19, 2026.
- 2026-07-22 Multiple firms remind investors of Aug 4 deadline; suit relates to failed NHS-Galleri trial
- 2026-07-24 At least 7 law firms issued alerts on July 23-24, urging investors to join the lawsuit before the August 4 deadline, alleging misrepresentations about trial results
- 2026-07-25 At least 6 independent law firms issued notices; class period set May 13, 2025 to Feb 19, 2026
- 2026-07-25 Multiple firms confirm August 4 lead plaintiff deadline; alleged class period May 13, 2025 to Feb 19, 2026
- 2026-07-27 Multiple firms remind of Aug 4 lead plaintiff deadline; class period May 13, 2025 to Feb 19, 2026
- 2026-07-28 Multiple firms remind of Aug 4 deadline after 50% stock drop.
- 2026-07-29 Multiple law firms announce class actions alleging GRAIL misled investors on NHS-Galleri trial; stock fell 50%; lead plaintiff deadline Aug 4.
- 2026-07-29 Multiple law firms re-issue reminders, investors must contact by Aug 4, class period May 13, 2025 - Feb 19, 2026
- 2026-07-31 Multiple law firms issue reminders, class action alleges securities fraud, investors must act by Aug 4
- 2026-08-01 Multiple law firms (BFA, Bronstein, DJS, Faruqi, Rosen, SBS, Gross, Robbins Geller) issued reminders today, with August 4 as the first deadline; class period alleged May 13, 2025 to Feb 19, 2026.
- 2026-08-01 Multiple law firms remind investors of August 4 deadline; class period covers May 13, 2025 to Feb 19, 2026
- 2026-08-03 Multiple firms remind of Aug 4 deadline for lead plaintiff applications
- 2026-08-04 Lead plaintiff deadline Aug 4; multiple firms issue reminders; alleged class period May 13, 2025–Feb 19, 2026
- 2026-08-04 Multiple firms issued reminders today; August 4 is the first deadline for lead plaintiff applications.
2026-07-30Company
GRAIL to Present at Canaccord Genuity 46th Annual Growth Conference
Management to attend, may discuss business progress and strategy
D1 +12.1% · +5d -10.9%
2026-07-29Earnings
GRAIL to Announce Second Quarter 2026 Financial Results
Company plans to release Q2 2026 financial results soon, exact date to be announced
D1 -1.5% · +5d +16.9%

$GRAL (GRAIL Inc.) — investor discussion on X

Five-factor rating: Sell (sector percentile 20.7%)

Most active credible voices on $GRAL

Recent headlines featuring $GRAL

$GRAL (GRAIL Inc.) — investor discussion on X

Five-factor rating: Sell (sector percentile 20.7%)

Most active credible voices on $GRAL

Recent headlines featuring $GRAL

GRAIL Q3 Revenue Up 4% on Volume, Price Cuts Ahead of FDA

Earnings report

GRAL Hits New 52-Week High on Heavy Volume

Halt: news pending

Earnings report

8-K: Item 2.02, Item 9.01

Earnings report

GRAIL Faces Multiple Securities Class Actions Alleging Fraud

GRAIL to Present at Canaccord Genuity 46th Annual Growth Conference

GRAIL to Announce Second Quarter 2026 Financial Results

Bull vs bear

Discussion

GRAIL Q3 Revenue Up 4% on Volume, Price Cuts Ahead of FDA

Earnings report

GRAL Hits New 52-Week High on Heavy Volume

Halt: news pending

Earnings report

8-K: Item 2.02, Item 9.01

Earnings report

GRAIL Faces Multiple Securities Class Actions Alleging Fraud

GRAIL to Present at Canaccord Genuity 46th Annual Growth Conference

GRAIL to Announce Second Quarter 2026 Financial Results